Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. -57 (Cancelled)

58. (Currently amended) A compound having a formula **(I)** ~~**selected from the group consisting of**~~:



(I)

~~**and**~~ and their pharmaceutically acceptable salts, wherein

R^1 is a C_5-C_{12} cycloalkyl group wherein said cycloalkyl portion is monocyclic or polycyclic;

P^1 is NHC(O)NH-;

P^2 is selected from the group consisting of -C(O)-, -CH(OH)-, -C(O)O-, -OC(O)-, -NHC(O)NH-, -OC(O)NH-, -NHC(O)O-, -C(O)NH- [[and]] -NHC(O)- and $-O(CH_2CH_2O)_q$;

P^3 is selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, $-NHS(O)_2R^2$, $-C(O)OR^2$ and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, substituted **C_1-C_4 alkyl,** ~~**or**~~ unsubstituted C_1-C_4 alkyl, substituted **C_3-C_8 cycloalkyl,** ~~**or**~~ unsubstituted C_3-C_8 cycloalkyl, substituted **aryl,** ~~**or**~~ unsubstituted aryl, ~~**and**~~ substituted **aryl C_1-C_4 alkyl and** ~~**or**~~ unsubstituted aryl C_1-C_4 alkyl;

the subscripts n and m are each independently 0 or 1, at least one of n or m is 1 and q is 0 to 3;

L^1 is substituted **C_2-C_6 alkylene** or unsubstituted C_2-C_6 alkylene;

L^2 is substituted **C_2-C_6 alkylene** or unsubstituted C_2-C_{12} alkylene.

59. (Currently amended) A compound having a formula **(I)** ~~**selected from the group consisting of**~~:



(I) ~~and~~ ~~(II)~~

and their pharmaceutically acceptable salts, wherein

R^1 is a member selected from the group consisting of C_5-C_{12} cycloalkyl, aryl, heteroaryl and combinations thereof, wherein said cycloalkyl portions are monocyclic or polycyclic;

P^1 is a primary pharmacophore selected from the group consisting of -NHC(O)NH-, -OC(O)NH-, -NHC(O)O-, $-CH_2C(O)NH-$, -C(O)NH- and -NHC(O)-;

P^2 is a secondary pharmacophore selected from the group consisting of -C(O)-, -CH(OH)-, $-O(CH_2CH_2O)_q-$, -C(O)O-, -OC(O)-, -NHC(O)NH-, -OC(O)NH-, -NHC(O)O-, -C(O)NH- and -NHC(O)-;

~~P^{2a} is selected from the group consisting of -C(O)- and -NHC(O)-;~~

P^3 is a tertiary pharmacophore selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, $-C(O)NHR^2$, $-C(O)NHS(O)_2R^2$, $-NHS(O)_2R^2$, $-C(O)OR^2$ and carboxylic acid analogs, ~~wherein~~ R^2 is a member selected from the group consisting of hydrogen, substituted **C_1-C_4 alkyl,** ~~or~~ unsubstituted C_1-C_4 alkyl, substituted C_3-C_8 **cycloalkyl,** ~~or~~ unsubstituted C_3-C_8 cycloalkyl, substituted ~~or~~ unsubstituted aryl, ~~and~~ substituted **aryl C_1-C_4 alkyl and** ~~or~~ unsubstituted aryl C_1-C_4 alkyl;

the subscripts n and m are each independently 0 or 1, and at least one of n or m is 1, and the subscript q is 0 to 3;

L^1 is a first linker selected from the group consisting of substituted **C_2-C_6 alkylene,** ~~and~~ unsubstituted C_2-C_6 alkylene, substituted **C_3-C_6 cycloalkylene,** ~~and~~ unsubstituted C_3-C_6 cycloalkylene, substituted **arylene,** ~~or~~ unsubstituted arylene, ~~and~~ substituted **heteroarylene and** ~~or~~ unsubstituted heteroarylene;

L^2 is a second linker selected from the group consisting of substituted **C_2-C_{12} alkylene,** ~~**and**~~ unsubstituted C_2-C_{12} alkylene, substituted **arylene,** ~~**and**~~ unsubstituted arylene, and combinations thereof~~**; and**~~

~~**A^1 is a member selected from the group consisting of an amino acid, a dipeptide and a dipeptide analog**~~.

60. (Cancel)

61. - 69. (Cancelled)

70. (Currently amended and withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of **any one of claims** ~~**claim**~~ 58 **and 59**.

71. - 104. (Cancel)

105. (Currently amended) The compound in accordance with any one of claims 58~~**, 60 and 95 to 98**~~ **and 59**, wherein P^3 is $-C(O)OR^2$ ~~**and**~~ **or** a carboxylic acid analog, ~~**wherein**~~ **and** R^2 is hydrogen, substituted **C_1-C_4 alkyl,** ~~**or**~~ unsubstituted C_1-C_4 alkyl, substituted **C_3-C_8 cycloalkyl** or unsubstituted C_3-C_8 cycloalkyl.

106. (New) The compound of any one of Claims 58 and 59, wherein P^3 is $-C(O)OR^2$ or a carboxylic acid analog, and R^2 is selected from the group consisting of hydrogen, methyl, and ethyl.

107. (New) The compound of any one of Claims 58 and 59, wherein R^1 is selected from the group consisting of C_5-C_{12} cycloalkyl, phenyl and naphthyl.

108. (New) The compound of any one of Claims 58 and 59, wherein R^1 is selected from the group consisting of C_5-C_{12} cycloalkyl and phenyl.

109. (New) The compound of any one of Claims 58 and 59, wherein R^1 is selected from the group consisting of cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, adamantyl, noradamantyl, and phenyl, and phenyl is optionally substituted with from one to three substituents selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 alkoxy, C_3-C_5 cycloalkyl and cyano.

110. (New) The compound of any one of Claims 58 and 59, wherein P^1 is selected from the group consisting of –NHC(O)CH-, -OC(O)NH- and –NHC(O)O-.

111. (New) The compound of any one of Claims 58 and 59, wherein P^1 is–NHC(O)CH-.

112. (New) The compound of any one of Claims 58 and 59, wherein L^1 is an alkylene of from 2 to 4 carbon atoms,

P^2 is not present; and

L^2 is an alkylene of from 2 to 8 carbon atoms.

113. (New) The compound of Claim 59, wherein the compound has formula (I),

wherein P^1 is selected from the group consisting of —NHC(O)NH—, -OC(O)NH— and —NHC(O)O—;

n is 0;

m is 1;

L^1 is selected from the group consisting of unsubstituted C_2-C_6 alkylene, unsubstituted C_3-C_6cycloalkylene, substituted C_3-C_6cycloalkylene, unsubstituted arylene and substituted arylene;

L^2 is selected from the group consisting of unsubstituted C_2-C_6 alkylene and substituted C_2-C_6 alkylene; and

P^3 is selected from the group consisting of C_2-C_6 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, —$C(O)NHR^2$, —$C(O)NHS(O)_2R^2$, —$NHS(O)_2R^2$, —$C(O)OR^2$ and carboxylic acid analogs, and R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1-C_4 alkyl and substituted aryl C_1-C_4 alkyl.

114. (New) A compound having the formula described in Tables 1-18 and their pharmaceutically acceptable salts.

115. (New) A compound having the formula:



and pharmaceutically acceptable salts thereof.

116. (New) A compound having the formula:



and pharmaceutically acceptable salts thereof.

117. (New) A compound having the formula:



and pharmaceutically acceptable salts thereof.